SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

LYRA

Lyra Therapeutics
BEARISH
Impact 8/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Delisting
Actionable Insight ▼ Bearish

Traders should anticipate reduced liquidity and wider bid-ask spreads as LYRA moves to the OTC Pink market. The delisting signals financial or operational distress, and the upcoming termination of SEC reporting will limit future disclosure. Monitor for potential going-private moves or dissolution.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
LYRA ▼ -47.53% at T+60d
SHORT call ✓ call won +47.53% · α vs SPY +53.68% · entry $0.8046 → $0.4221
Entry = T+0 close
Apr 17, 2026
via day close
T+1d
-7.28%
call +7.28% · α +7.09%
$0.7460
settled 6mo ago
T+5d
-11.68%
call +11.68% · α +12.24%
$0.7106
settled 6mo ago
T+20d
-6.79%
call +6.79% · α +12.16%
$0.7500
settled 6mo ago
T+60d
-47.53%
call +47.53% · α +53.68%
$0.4221
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Lyra Therapeutics announced it will voluntarily file a Form 25 to delist its stock from Nasdaq, accelerating the deregistration process after Nasdaq suspended trading in March 2026. The stock will continue trading on the Pink Limited Market, and the company plans to file Form 15 to terminate its SEC reporting obligations.

Key Facts

  • Lyra Therapeutics is voluntarily filing Form 25 to delist from Nasdaq on April 20, 2026.
  • Trading in LYRA stock was already suspended by Nasdaq on March 17, 2026.
  • The delisting is expected to become effective 10 days after Form 25 is filed.
  • The company plans to file Form 15 to terminate SEC registration and suspend reporting obligations.
  • Shares will continue to trade on the Pink Limited Market post-delisting.

Financial Impact

Non-financial but structurally significant: loss of exchange listing and public reporting status reduces liquidity, transparency, and institutional investor eligibility.

liquiditytransparencyinvestor basecompliance costs

Risk Factors

  • Severely reduced market liquidity and investor access post-delisting.
  • Lack of ongoing SEC reporting will increase information asymmetry and investment risk.
  • Potential perception of distress or lack of corporate governance transparency.

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276116
4 reports for LYRA
Performance horizon
67% Hit rate @ T+60 2 of 3 directional calls Went positive at some point 2 of 3 best @ T+60▲ +47.53%Apr 17, 2026
Filters
Rows
Reports for LYRA — sortable, filterable
TypeNow
Apr 30, 2026
25w ago
15-12G
BEARISH ★ 7/10
$0.7050 $0.5200▲ +26.24%▲ +29.35%$0.1900 (+73.05%)
Apr 17, 2026
27w ago
8-K
BEARISH ★ 6/10
$0.8046 $0.4221▲ +47.53%▲ +53.68%$0.1900 (+76.39%)
Apr 17, 2026
27w ago
Press Release
BEARISH ★ 8/10
$0.8046 $0.4221▲ +47.53%▲ +53.68%$0.1900 (+76.39%)
Apr 10, 2026
28w ago
8-K
BEARISH ★ 7/10
$0.6500 $0.7093▼ −9.13%▲ +1.20%$0.1900 (+70.77%)
Showing 4 of 4

US Market Status

Market Closed — Opens Thu (10h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026